Scarica l'app Stockscreener
7.43
0.13%
0.010
Dopo l'orario di chiusura:
7.48
0.05
+0.67%
Regenxbio Inc Borsa (RGNX) Ultime notizie
ETFs Investing in REGENXBIO, Inc. Stocks - TradingView
Net income before discontinued operations of REGENXBIO, Inc. – HAN:RB0 - TradingView
H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data - Investing.com
REGENXBIO Inc. (RGNX) stock price, news, quote and history - Yahoo Finance Singapore
REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why is Regenxbio stock climbing today? By Investing.com - Investing.com Australia
REGENXBIO reports three-year ALTITUDE DRSS data - Mugglehead Investment Magazine
REGENXBIO stock reports 60 percent three-year eye study response - AD HOC NEWS
Stifel reiterates Regenxbio stock rating on gene therapy data - Investing.com
Why is Regenxbio stock climbing today? - Investing.com
Regenxbio stock gains on positive gene therapy trial data - Investing.com
Regenxbio stock gains on positive gene therapy trial data By Investing.com - Investing.com Australia
REGENXBIO reports three-year sura-vec Phase II results - grafa.com
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
RGNX Looks 52.3% Undervalued on GF Value™ Despite Challenges - GuruFocus
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting - PR Newswire
Sarepta Settles Regenxbio’s Patent Infringement Claims in $39M Deal - GenomeWeb
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Stocktwits
Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund - Endpoints News
REGENXBIO and Sarepta Resolve ELEVIDYS Patent Litigation with $39 Million Settlement - Kalkine Media
RGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold - Stocktwits
Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date - TradingView
Responsive Playbooks and the RGNX Inflection - Stock Traders Daily
REGENXBIO stock edges lower as short interest stays elevated - AD HOC NEWS
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a Potential 188.83% Upside in Biotech Innovation - DirectorsTalk Interviews
REGENXBIO Inc. stock steadies after Morgan Stanley conference appearance - AD HOC NEWS
RGNX: Late-stage gene therapy programs advance toward commercialization, with strong efficacy and safety data - TradingView
RGNX: Late-stage gene therapy programs advance toward commercialization, with strong data and funding - TradingView
REGENXBIO at Morgan Stanley conference: late-stage gene therapy push - Investing.com
REGENXBIO at 2026 Global Healthcare Conference: pipeline, cash runway By Investing.com - Investing.com Nigeria
REGENXBIO at 2026 Global Healthcare Conference: pipeline, cash runway - Investing.com
Certain Warrants of REGENXBIO Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2026. - marketscreener.com
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Wet Age-Related Macular Degeneration Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research - Barchart.com
REGENXBIO to present at two major healthcare investor conferences in September 2026 - Pluang
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
This REGENXBIO Insider Increased Their Holding In The Last Year - 富途牛牛
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance
REGENXBIO CTO Malzahn Craig Retains 81,960 Shares After Forfeiture on September 1, 2026 - Kalkine Media
REGENXBIO CFO Chan Mitchell Forfeits 4,902 Shares at $9.32 Each (NASDAQ: RGNX) - Kalkine Media
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting - Kalkine Media
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances - streetwisereports.com
REGENXBIO (RGNX) Slips 1.86% to $9.48 as Gene Therapy Stock Presses Toward SupportTriangle Correction - careplusvn.com
REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy - Streetwise Reports
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
People on the Move: Greg Ciongoli Joins REGENXBIO’s Board of Directors - BioBuzz
Regenxbio stock surges on director share purchases By Investing.com - Investing.com Nigeria
Regenxbio stock surges on director share purchases - Investing.com
REGENXBIO : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
REGENXBIO's Hunter Syndrome Gene Therapy Hit With New FDA Clinical Hold Over Spine MRI Findings - BioBuzz
Regenxbio's FDA Hold Threatens Voucher Windfall, Analysts Slash Targets - finance.biggo.com
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold - Sahm
REGENXBIO Adds Greg Ciongoli to Board Ahead of Commercial Expansion - citybiz
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy - Yahoo Finance
REGENXBIO says FDA places RGX-121 on clinical hold; BLA resubmission not expected soon - TradingView
FDA places clinical hold on Regenxbio’s gene therapy for Hunter Syndrome - The Mighty 790 KFGO
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):